Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases
- PMID: 14697885
- DOI: 10.1016/S0161-813X(03)00090-1
Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases
Abstract
The monoamine oxidase (MAO) metabolites of norepinephrine (NE) or epinephrine (EPI) and of dopamine (DA) are 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) and 3,4-dihydroxyphenylacetaldehyde (DOPAL), respectively. The toxicity of these catecholamine (CA) MAO metabolites was predicted over 50 years ago. However, until our recent chemical synthesis of these CA aldehyde metabolites, the hypothesis about their toxicity could not be tested. The present paper reviews recent knowledge gained about these compounds. Topics to be reviewed include: chemical synthesis and properties of DOPEGAL and DOPAL; in vitro and in vivo toxicity of CA aldehydes; subcellular mechanisms of toxicity; free radical formation by DOPEGAL versus DOPAL; mechanisms of accumulation of CA aldehydes in Alzheimer's disease (AD) and Parkinson's disease (PD) and potential therapeutic targets in Alzheimer's disease and Parkinson's disease.
Similar articles
-
3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.Brain Res Mol Brain Res. 2001 Sep 10;93(1):1-7. doi: 10.1016/s0169-328x(01)00120-6. Brain Res Mol Brain Res. 2001. PMID: 11532332
-
Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography.Anal Biochem. 1999 Aug 15;273(1):111-6. doi: 10.1006/abio.1999.4196. Anal Biochem. 1999. PMID: 10452806
-
Differential Susceptibilities of Catecholamines to Metabolism by Monoamine Oxidases.J Pharmacol Exp Ther. 2021 Nov;379(3):253-259. doi: 10.1124/jpet.121.000826. Epub 2021 Sep 9. J Pharmacol Exp Ther. 2021. PMID: 34503991 Free PMC article.
-
The catecholaldehyde hypothesis: where MAO fits in.J Neural Transm (Vienna). 2020 Feb;127(2):169-177. doi: 10.1007/s00702-019-02106-9. Epub 2019 Dec 5. J Neural Transm (Vienna). 2020. PMID: 31807952 Free PMC article. Review.
-
3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.Curr Drug Targets CNS Neurol Disord. 2003 Apr;2(2):143-8. doi: 10.2174/1568007033482913. Curr Drug Targets CNS Neurol Disord. 2003. PMID: 12769806 Review.
Cited by
-
Brain effects of chronic IBD in areas abnormal in autism and treatment by single neuropeptides secretin and oxytocin.J Mol Neurosci. 2005;25(3):259-74. doi: 10.1385/JMN:25:3:259. J Mol Neurosci. 2005. PMID: 15800379
-
Mitochondrial respiratory dysfunction and mutations in mitochondrial DNA in PINK1 familial parkinsonism.J Bioenerg Biomembr. 2009 Dec;41(6):509-16. doi: 10.1007/s10863-009-9252-4. J Bioenerg Biomembr. 2009. PMID: 19904588 Review.
-
Cocaine sobers up.Nat Med. 2010 Sep;16(9):969-70. doi: 10.1038/nm0910-969. Nat Med. 2010. PMID: 20823878 No abstract available.
-
Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro.J Neural Transm (Vienna). 2011 Jul;118(7):987-95. doi: 10.1007/s00702-011-0616-7. Epub 2011 Mar 4. J Neural Transm (Vienna). 2011. PMID: 21373759
-
Binge ethanol exposure increases the Krüppel-like factor 11-monoamine oxidase (MAO) pathway in rats: Examining the use of MAO inhibitors to prevent ethanol-induced brain injury.Neuropharmacology. 2016 Jun;105:329-340. doi: 10.1016/j.neuropharm.2016.01.024. Epub 2016 Jan 22. Neuropharmacology. 2016. PMID: 26805422 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical